Expert Perspective

Long COVID: New Info on Who Is Most Likely to Get It


 

History of Immune Dysfunction, Diabetes, Elevated Body Mass Index (BMI)

Immune dysfunction, a history of recurrent infections, or chronic sinus infections are also common among patients under Dr. Azola and her team’s care. Those who have arthritis or other autoimmune diseases such as lupus also appear more vulnerable, Dr. Bayley said, along with patients who have diabetes or a little overweight.

Recent research out of the University of Queensland found that being overweight can negatively affect the body’s immune response to the SARS-CoV-2 virus. Blood samples collected 13 months after infection, for example, found that individuals with a higher BMI had lower antibody activity and a reduced percentage of relevant B cells that help build antibodies to fight the virus. Being overweight did not affect the antibody response to the COVID-19 vaccines, however, giving further support for vaccination over infection-induced immunity as an important protective factor, researchers said.

Narrowing the Information Gap

The latest Centers for Centers for Disease Control and Prevention’s Household Pulse Survey estimates that 14% of all American adults have had long COVID at some point, with more than 5% of the entire adult population currently experiencing long COVID. With millions of Americans affected, experts and advocates highlight the importance of bridging the knowledge gap with primary care doctors.

Long COVID specialists said understanding these connections helps guide treatment plans and manage symptoms, such as finding the right medications, improving tolerance, optimizing sleep, applying cognitive strategies for brain fog, dietary changes, respiratory exercises to help with shortness of breath, and finding the fine line between what causes PEM and what doesn’t.

“Whenever you see a disease like this one, you always have to ask yourself, is there an alternative way of looking at this that might explain what we’re seeing?” said Dr. Bayley. “It remains to be said that all bets are still open and that we need to continue to be very broad thinking about this.”

A version of this article appeared on Medscape.com.

Pages

Recommended Reading

Nirmatrelvir-ritonavir ineffective at reducing most post-COVID conditions
MDedge Internal Medicine
People with long COVID don’t show signs of brain damage
MDedge Internal Medicine
Second infection hikes long COVID risk: Expert Q&A
MDedge Internal Medicine
A new long COVID explanation: Low serotonin levels?
MDedge Internal Medicine
Sensory comeback: New findings show the path to smell and taste recovery after COVID
MDedge Internal Medicine
Long COVID and mental illness: New guidance
MDedge Internal Medicine
Chest pain with long COVID common but undertreated
MDedge Internal Medicine
New tests may finally diagnose long COVID
MDedge Internal Medicine
Some reasons to get off the fence about COVID booster
MDedge Internal Medicine
Monoclonal Antibodies: A New Treatment for Long COVID?
MDedge Internal Medicine